All drug safety articles
-
OpinionA new regulatory paradigm for increased robustness in chemical testing
Non-animal methods could revolutionise how we assess toxicity
-
OpinionThe side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance
-
OpinionThe ins and outs of vaccine trials
Derek Lowe lays out how the trials work, and why they get paused and restarted
-
BusinessRussian vaccine launch shocks scientists
Sputnik V to be approved without large human trial data
-
ResearchCommon inactive drug ingredients not as inert as thought
38 out of 639 excipients tested interact with toxicity-related proteins, some reaching levels that might produce unwanted effects
-
NewsTelemedicine abortion provider locks horns with US drug regulator
Food and Drug Administration urged to take action against abortion charity by US politicians
-
PodcastLimulus Amebocyte Lysate
Frances Addison takes a look at the discovery that brought horseshoe crabs to the heart of the pharmaceutical industry
-
ResearchBlood pressure drug reacts with membrane lipids
Lipidation products add to evidence that biological membranes are far from chemically inert
-
NewsFears that US 'right to try' law could put patients at risk
Legislation will give terminally ill patients the option of taking medicines that have had little testing
-
NewsAnalytical test strip fights fentanyl overdoses
Simple chemical analysis helps drug users prevent overdosing on deadly opioid
-
OpinionHow safe should drugs be?
What does spotting new risks in approved medicines say about how effective regulators are?
-
Business
Judge slashes fines in drug safety case
Takeda and Eli Lilly’s $9 billion damages in diabetes trial reduced to $38 million
-
Business
Boehringer to settle blood thinner drug suits for $650m
Company confident in drug safety but says court cases are too risky
-
BusinessMissing safety risk emails draw $9bn Actos fine
Judge finds absence of Takeda documentation in bladder cancer case ‘disturbing’
-
Business
$1.2bn J&J deceptive marketing fine overturned
Supreme court reverses decision to fine firm over Risperdal promotion
-
Business
US turnaround on Avandia restrictions
Researchers accuse regulator of face-saving U-turn over diabetes medication safety
-
News
Rough patch for India’s clinical trial industry
Bad publicity has added to the woes of an industry worried by regulatory uncertainty
-
BusinessMis-selling lands J&J with $2.2bn fine
Company found guilty of promoting three drugs for unapproved uses
-
News
Supreme court ruling brings clinical trials to a halt in India
Pressure from campaign group precipitates action that puts 162 drug trials on ice
-
NewsCall to overhaul liver toxicity testing
Outdated tests could be causing drug candidates to be scrapped without reason, say scientists